Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | HCK | P08631 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399189 | 0.80 | CYP1A2 (0.37) | QPCTQPCTLCYP1A2PIK3CAKMT2A | |
| SCHEMBL28323180 | 0.78 | CYP1A2 (0.45) | CYP1A2PIK3CAKMT2AMEN1ALDH1A1 | |
| SCHEMBL19103239 | 0.78 | P2RX3 (0.37) | KMT2ALRRK2 | |
| SCHEMBL17541424 | 0.77 | FTO (0.39) | CYP1A2KMT2AMEN1ALDH1A1FTO | |
| SCHEMBL1180511 | 0.77 | NUDT1 (0.44) | CYP1A2METAP2KMT2AALDH1A1KDM4E | |
| SCHEMBL2817366 | 0.77 | ALDH1A1 (0.43) | GAACYP1A2KMT2AALDH1A1KDM4E | |
| SCHEMBL13460628 | 0.76 | DHFR (0.43) | LRRK2TSHR | |
| SCHEMBL8888 | 0.76 | QPCT (0.40) | QPCTQPCTLGAACYP1A2CRHR1 | |
| SCHEMBL3816071 | 0.76 | KMT2A (0.52) | QPCTQPCTLCYP1A2CRHR1METAP2 | |
| SCHEMBL23994815 | 0.74 | QPCT (0.39) | QPCTQPCTLGAACYP1A2CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | claimed |
| CN-119775260-A | Pyrimidine-2, 4 (1H, 3H) -dione compounds, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2025-04-08 | — | — | CN | claimed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | claimed |
| US-20220195497-A1 | HYBRIDIZING all-LNA OLIGONUCLEOTIDES | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2022-06-23 | — | — | US | claimed |
| EP-3980554-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-113939599-A | Hybrid all-LNA oligonucleotides | 豪夫迈·罗氏有限公司 | 2022-01-14 | — | — | CN | claimed |
| WO-2020245377-A1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-10 | — | — | WO | claimed |
| EP-4678632-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-4662326-A1 | LIGAND-ENABLED TRANSANNULAR C-H FUNCTIONALIZATION OF CYCLOALKANE CARBOXYLIC ACIDS | The Scripps Research Institute (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250346557-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | AGC Inc. (JP) | 2025-11-13 | — | — | US | disclosed |
| EP-4560315-A2 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-3980554-B1 | HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES | HOFFMANN LA ROCHE (CH) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024185814-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | ＡＧＣ株式会社 | 2024-09-12 | — | — | WO | disclosed |
| WO-1996014073-A1 | TREATMENT OF UROGENITAL CANCER WITH BORON NEUTRON CAPTURE THERAPY | EMORY UNIVERSITY (US) | 1996-05-17 | — | — | WO | disclosed |
| EP-0550580-A1 | URACIL REDUCTASE INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| EP-0539442-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-05-05 | — | — | EP | disclosed |
| WO-1992004901-A1 | URACIL REDUCTASE INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-02 | — | — | WO | disclosed |
| WO-1992001452-A1 | ENZYME INACTIVATORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-02-06 | — | — | WO | disclosed |
| US-4929723-A | Process for preparing 2-deoxynucleosides | ETHYL CORPORATION (US) | 1990-05-29 | — | — | US | disclosed |
| EP-0300765-A2 | Process for preparing 2-deoxynucleosides | ETHYL CORPORATION (US) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346557-A1 | METHOD FOR PRODUCING ARYL COMPOUND CONTAINING TRITYLSULFANYL GROUP | STS, TST, CYP3A5 | QPCT 2628/4885QPCTL 1577/4885GAA 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.